PSI-401 / Prostemics - LARVOL DELTA

Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus. (PubMed, Microb Cell Fact) - "In summary, these findings suggest that the engineered L. plantarum strain pSIP401-HA1-ZN-3 can be considered as an alternative approach for developing a novel vaccine during an swine influenza A pandemic."

Journal • Preclinical • Infectious Disease • Respiratory Diseases

Prostemics (203690) New drug development using exosomes [Google translation] (Maekyung Media Group) - "Prostemics' representative pipeline, PSI-401...Currently, IND Filing is in progress to enter the US FDA clinical trial. In the next year, it is planned to proceed with phase 1 clinical trials for inflammatory bowel disease (IBD)...and plans to complete phase 1 and enter phase 2 by the end of 2022...and plans to promote commercialization by obtaining approval from the Ministry of Food and Drug Safety."

IND • New P1 trial • New P2 trial • Trial completion date • Inflammatory Bowel Disease